BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced plans to establish an Enterprise Solutions Hub in the Philippines.

Scribe Therapeutics Inc. today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, Calif. and virtually from May 16-20, 2023.

Reata Pharmaceuticals, Inc. announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company’s business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that the enrollment of first-line (1L) CLDN18.2 expressing Gastric / Gastro-esophageal Junction (G/GEJ) adenocarcinoma patients in cohorts C and G for the China Phase II study (Transtar-102, NCT04495296) of its high affinity humanized ADCC-enhanced anti-CLDN18.2 monoclonal antibody Osemitamab (TST001) has been completed.

CANbridge Pharmaceuticals Inc. announced that data on the novel second-generation gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, will be presented at the American Society of Gene and Cell Therapy 26th Annual Meeting, May 16-20, Los Angeles, CA.

EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe.

Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug ‘Xafty’.

Lannett Company, Inc. announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to effectuate the transactions contemplated by the Restructuring Support Agreement announced on May 1, 2023.